Scancell trial update 'very positive', says broker
Portfolio Pulse from
Panmure Liberum has reiterated its 'buy' recommendation for Scancell Holdings PLC shares following a positive update from its phase II SCOPE clinical trial for the cancer vaccine SCIB1.
November 18, 2024 | 9:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scancell Holdings received a 'buy' recommendation from Panmure Liberum after a positive update from its phase II SCOPE trial for the SCIB1 cancer vaccine.
The positive update from the phase II SCOPE trial for SCIB1 is likely to boost investor confidence, leading to a potential increase in Scancell's stock price. The reiteration of a 'buy' recommendation by Panmure Liberum further supports a positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90